Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Oregon Health and Science University
New users of the LNG IUD will be eligible. Subjects will be randomized to receive tamoxifen 10 mg twice daily for 7 days or placebo. Study drug will be started 3 weeks after placement of the IUD. Subjects will maintain a record of daily bleeding and spotting using an electronic text messaging diary.
Age
15–45
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
initiating use of 52mg levonorgestrel-releasing IUD for contraceptive purposes
access to reliable cell phone
willing to receive and respond to daily text or email message to assess bleeding
You may not be if
using IUD for indication other than contraception
postpartum within 6 months, pregnant, or breastfeeding
removal and replacement of IUD
undiagnosed abnormal uterine bleeding prior to placement of IUD
bleeding dyscrasia
anti-coagulation use
active cervicitis
allergy to tamoxifen
history of venous thromboembolism
personal history of breast or uterine malignancy
use of medication contraindicated with use of tamoxifen (coumadin, letrozole, bromocriptine, rifampicin, aminoglutethimide, phenobarbital)
